Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes.

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62

HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47

Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl (2004) 3.46

The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33

The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology (2004) 2.36

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23

Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl (2006) 1.99

Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96

Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol (2000) 1.66

Liver transplantation for polycystic liver disease. Arch Surg (1990) 1.61

Somatostatin receptors. Biochim Biophys Acta (2003) 1.49

Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47

Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol (2015) 1.41

New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol (2005) 1.40

Medical and surgical treatment options for polycystic liver disease. Hepatology (2010) 1.39

Clinical profile of autosomal dominant polycystic liver disease. Hepatology (2003) 1.37

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30

Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol (2009) 1.17

Isolated polycystic liver disease. Adv Chronic Kidney Dis (2010) 1.08

Liver transplantation for polycystic liver disease. Liver Transpl (2001) 1.06

Surgical management of polycystic liver disease. World J Gastroenterol (2007) 1.06

Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg (1997) 1.06

Regulation and deregulation of cholangiocyte proliferation. J Hepatol (2000) 1.02

Liver transplantation for polycystic liver disease--indications and outcome. Transplant Proc (2003) 1.02

Polycystic liver disease is genetically heterogeneous: clinical and linkage studies in eight Finnish families. J Hepatol (2003) 1.00

Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation (2006) 0.96

Occurrence of an inhibitory guanine nucleotide-binding regulatory component of the adenylate cyclase system in cyc- variants of S49 lymphoma cells. Eur J Biochem (1983) 0.95

Polycystic liver diseases. Dig Liver Dis (2010) 0.93

Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther (2003) 0.93

Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. Gut (1995) 0.93

Liver transplantation for adult polycystic liver disease. Hepatology (1998) 0.91

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology (1995) 0.87

Polycystic liver disease and liver transplantation: single-institution experience. Transplant Proc (2009) 0.85

Liver transplantation for adult polycystic liver disease. Liver Transpl Surg (1996) 0.84

Infection of hepatic cysts in polycystic disease. World J Surg (1984) 0.84

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc (2015) 0.82

Living-donor liver transplantation for polycystic liver disease. Transplantation (2004) 0.81

Liver transplantation in patients with polycystic liver disease. Transplant Proc (1997) 0.80

Autosomal dominant polycystic liver disease: a second family. Clin Genet (1982) 0.80

Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3',5'-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. Endocrinology (1985) 0.79

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Semin Nephrol (2015) 0.76

Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology (2016) 0.76